Stock vs Stock Comparison

Baxter International Inc. vs Johnson & Johnson

JNJ wins the Tale of the Tape 8–1.

BAX$18.68
JNJ$222.89

🏆 Tale of the Tape

18
BAXJNJ
-8.5%Profitability (Net Margin)28.5%
Valuation (P/E)26.1x
-1.0%Efficiency (ROIC)18.3%
5/9Health (Piotroski F)4/9
2.1Safety (Altman Z)4.0
5.7%Growth (Rev YoY)6.0%
-1.04Risk (Sharpe 1Y)2.69
2.29xBalance Sheet (D/E)1.44x
1.97%FCF Yield3.25%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.169
252-Day Correlation
-0.024
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricBAXJNJ
Market Cap$9.7B$542.4B
P/E Ratio26.1x
Forward P/E9.3x17.7x
P/B1.60x6.68x
Dividend Yield1.06%2.38%
Beta0.620.26

Quantitative Metrics

MetricBAXJNJ
DCF Fair Value$8.07$134.24
DCF Upside-54.2%-43.6%
Piotroski F5/94/9
Altman Z2.103.97
Beneish M-2.66-2.27
FCF Yield1.97%3.25%
Net Debt/EBITDA9.8x0.5x
ROIC-1.0%18.3%
WACC6.3%7.7%
ROIC – WACC-7.2pp10.5pp
Gross Margin30.0%67.9%
Net Margin-8.5%28.5%
Rev Growth YoY5.7%6.0%
Sharpe (1Y)-1.042.69
Max Drawdown 3Y-16.0%
FCF Payout Ratio108%64%

BAX Price

Loading chart...

JNJ Price

Loading chart...

ETF Exposure

BAX found in:

XHE1.80%
RSP0.21%
VBR0.21%
XLV0.18%
VHT0.15%
VB0.12%
VYM0.04%
SCHV0.04%
SPYV0.03%
IWD0.03%
SPLG0.02%
IVV0.02%
SCHX0.02%
SCHB0.02%
SPY0.02%
ITOT0.02%
SPTM0.01%
URTH0.01%
ACWI0.01%
VOO0.01%

JNJ found in:

XLV10.42%
IYH10.14%
VHT8.84%
HDV6.84%
MTUM3.76%
DIA2.83%
MGV2.75%
DGRO2.64%
VIG2.49%
VYM2.30%
VTV2.16%
DGRW2.02%
SCHV2.02%
IWD1.94%
QUS1.81%
XPH1.74%
VONV1.69%
NOBL1.58%
VFMV1.42%
VFMO1.02%
SCHX0.96%
SPYG0.94%
SDY0.93%
VOO0.90%
SCHB0.90%
SPY0.87%
IVV0.85%
VONE0.84%
SPTM0.81%
VTI0.80%
SPYV0.79%
SPLG0.76%
ITOT0.75%
URTH0.70%
ACWI0.57%
VT0.49%
RSP0.21%
VFVA0.15%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

BAX vs JNJ: Head-to-Head Analysis

Baxter International Inc. (BAX) and Johnson & Johnson (JNJ) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, JNJ leads 8–1 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, BAX generates a return on invested capital (ROIC) of -1.0% compared to JNJ's 18.3%. This suggests JNJ is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between BAX and JNJ is 0.169, indicating low correlation, making them an effective diversification pair in a portfolio context.

BAX appears in 20 ETFs tracked by SecuritiesDB, while JNJ appears in 39 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, BAX or JNJ?

Our quantitative analysis compares BAX and JNJ across nine fundamental dimensions. JNJ wins the Tale of the Tape 8–1. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are BAX and JNJ correlated?

The 252-day correlation between BAX and JNJ is 0.169. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.